Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ITEOS THERAPEUTICS, INC.

(ITOS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Iteos Therapeutics

11/26/2021 | 07:01am EST


© MT Newswires 2021
All news about ITEOS THERAPEUTICS, INC.
01/11ITEOS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
01/10ITeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief S..
AQ
01/10iTeos Therapeutics, Inc. Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer
CI
01/06INSIDER SELL : Iteos Therapeutics
MT
01/05ITEOS THERAPEUTICS, INC.(NASDAQGM : ITOS) added to S&P 600
CI
01/05ITEOS THERAPEUTICS, INC.(NASDAQGM : ITOS) added to S&P Composite 1500
CI
01/05ITEOS THERAPEUTICS, INC.(NASDAQGM : ITOS) added to S&P 600 Health Care
CI
01/05ITEOS THERAPEUTICS, INC.(NASDAQGM : ITOS) added to S&P 1000
CI
01/03ITeos to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
01/03Wall Street Futures Mostly Higher, Tesla Fuels Momentum in First Trading Day of 2022
MT
More news
Analyst Recommendations on ITEOS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 190 M - -
Net income 2021 77,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 16,9x
Yield 2021 -
Capitalization 1 246 M 1 246 M -
Capi. / Sales 2021 6,57x
Capi. / Sales 2022 3,82x
Nbr of Employees 74
Free-Float -
Chart ITEOS THERAPEUTICS, INC.
Duration : Period :
iTeos Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ITEOS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 35,33 $
Average target price 50,20 $
Spread / Average Target 42,1%
EPS Revisions
Managers and Directors
Michel Detheux President, Chief Executive Officer & Director
Matthew Gall Chief Financial Officer
David L. Hallal Chairman
Joanne Jenkins Lager Chief Medical Officer
Yvonne McGrath Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ITEOS THERAPEUTICS, INC.-24.12%1 246
GILEAD SCIENCES, INC.-7.26%84 470
REGENERON PHARMACEUTICALS-4.16%63 282
VERTEX PHARMACEUTICALS3.18%57 608
WUXI APPTEC CO., LTD.-12.11%47 873
BIONTECH SE-37.66%38 812